IL Dong Pharmaceutical KRX:249420KOSPI
일동제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days3
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, IL Dong Pharmaceutical reported revenue of ₩148bn, up 6.8% year on year, and operating profit of ₩2.0bn. IL Dong Pharmaceutical (일동제약) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 2 articles. It was most often mentioned alongside Tomatosystem.
IL Dong Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩148bn | +6.8% | ₩2.0bn | ₩5.1bn |
| Q1 2026 | ₩142bn | +4.4% | ₩9.2bn | ₩7.4bn |
| Q4 2025 derived | ₩147bn | -5.6% | ₩7.9bn | ₩5.6bn |
| Q3 2025 | ₩145bn | -6.7% | ₩6.8bn | ₩21.5bn |
| Q2 2025 | ₩138bn | -9.0% | ₩596m | −₩3.9bn |
| Q1 2025 | ₩136bn | -10.0% | ₩4.2bn | ₩500m |
| Q4 2024 derived | ₩156bn | +3.1% | ₩8.4bn | ₩2.9bn |
| Q3 2024 | ₩156bn | +4.3% | ₩3.6bn | −₩9.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
IL Dong Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
- 3
